
Herborium Group is a developer and marketer of herbal nutritional supplements. Herborium's product line includes Traditional Chinese Medicine herbal blends designed to clear up acne (AcnEase), boost energy (Energy Restoration), and heighten sexual performance (Lasting Pleasure for women, MaleForce for men). Herborium sells it products in the US, the UK, and continental Europe through a network of distributors, specialty retailers, such as natural foods stores, and online marketplaces. The company's founder, president and CEO Agnes Olszewski and director James Gilligan hold about 70% of the company's shares.

Amarillo Biosciences, Inc. company was founded in 1984 and is based in Amarillo, Texas. Amarillo Biosciences, Inc. (AMAR) is engaged in developing biologics for the treatment of human and animal diseases. The Company has a technology for a less toxic method of administration, low-dose oral interferon, in United States Food and Drug Administration (FDA) Phase II clinical trials. The Company has developed a dietary supplement and an interferon alpha lozenge, but, as of December 31, 2008, had not commenced any product commercialization activities. Injectable interferon is an immune modulator used to treat viral and autoimmune diseases and cancer. Orally delivered interferon binds to mucosal cells in the mouth and throat resulting in stimulation of immune mechanisms, and has been shown to activate hundreds of immune system genes in the peripheral blood. As of December 31, 2008, the Company has a Phase II study in progress in the United States to treat oral warts in human immunodeficiency virus-positive (HIV+) patients (Orphan Drug Designation).

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

Luitpold Pharmaceuticals earns its gold from the businesses of drugs and medical devices. Luitpold markets and manufactures injectable products used to treat an array of ailments including kidney disease. Luitpold also manufactures materials used in dental bone grafting and bone regeneration and treatments for equine and canine joint diseases. The company, which targets its products primarily to hospitals and clinics in US and Canadian markets, operates through four divisions: American Regent, Luitpold Animal Health, Osteohealth, and Contract Manufacturing. Originally a German company named after a Bavarian prince, Luitpold is a subsidiary of one of Japan's largest pharmaceutical companies, Daiichi Sankyo.

Matrixx Initiatives, Inc., through its subsidiaries, engages in the development, production, marketing, and sale of over-the-counter (OTC) healthcare products. It offers Zicam Cold Remedy nasal pump, a homeopathic nasal gel that reduces the duration and severity of the common cold; Zicam Cold Remedy Swabs for consumers, who dislike nasal sprays; and Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts, Zicam Cold Remedy Oral Mist, Zicam Cold Remedy RapidMelts + Vitamin C, and Zicam Cold Remedy RapidMelts + Vitamin C and Echinacea, which are oral cold remedy products that deliver a dose of ionic zinc to the oral mucosa. The company also provides Zicam Allergy Relief, a homeopathic nasal gel formula to control allergy symptoms for sufferers of hay fever and upper respiratory allergies; Zicam Extreme Congestion Relief, a nasal gel for relief of nasal congestion and sinus pressure; and Zicam Sinus Relief that provides the benefit of the product with the aromatic strength of a cooling menthol/eucalyptus blend. In addition, it offers Zicam Cough Spray products to deliver cough relief and soothe throat irritation, including Zicam Cough Max, a liquid spray formulation that provides relief. Further, the company offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms; and Xcid, a creamy antacid product. It sells products directly to food, drug, mass market, and wholesale warehouse retailers in the United States, as well as to distributors that sell to retail establishments under the Zicam, Nasal Comfort, and Xcid brands.

Nutraceutical International Corp. was founded in 1993 and is based in Park City, Utah. Nutraceutical International Corporation engages in the manufacture, marketing, distribution, and retail of branded nutritional supplements and other natural products in the United States and internationally. The company offers vitamins and minerals, herbs, specialty formulas, personal care products, homeopathics, functional foods, and other products in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, creams, sprays, powders, and whole herbs. It also publishes, prints, and markets a line of books and booklets to book distributors, national retail bookstores, and health and natural food stores; distributes branded products of certain third parties; and owns neighborhood natural food markets and health food stores. Nutraceutical International sells its products primarily to and through domestic health and natural food stores.

Formerly known as Stone Electronic Technology Limited, Stone Group Holdings Limited (Stock code: 409) was established on September 3, 1987. After a successful restructuring exercise in 1993, the Company became the first non-state-owned share-holding company in the PRC listed on the Stock Exchange of Hong Kong in August 1993. It is principally engaged in IT electronic & media – related business in mainland China, healthcare products business and investment business.The Company's IT electronic and media-related business includes the manufacture and distribution of traditional electronic products and the operation of internet café chain. Electronic products include dot matrix printer and value-added tax control machine with patented intellectual property, and the Group also acts as the agent and distributor of industrial controllers, uninterrupted power system equipment, digital graphics, semiconductors, computers etc.. Product coverage includes SIEMENS, FUJI. The internet café chain – Sunnet café is located in Guangdong Province.

Genzyme Diagnostics was founded in 1981. A division of Genzyme, it develops, manufactures, and distributes "in vitro" diagnostic products, including point-of-care tests. The division also produces the raw materials (such as enzymes and antibodies used in tests for diabetes, cholesterol, and pancreatitis) and chemical reagents used by other diagnostic test manufacturers to make their own diagnostic tests. The company's point-of-care products (tests administered at a patient's bedside) include tests for strep A, mononucleosis, and bacterial vaginitis; it also offers several different pregnancy tests.

MIGENIX likes to pick up compounds after they've been discovered, and shepherd them through to late-stage clinical development. After that point, the company is happy to license them out and hopefully reap the benefits. MIGENIX has partnered with Cadence Pharmaceuticals to shoulder the cost of putting its omiganan gel through Phase III clinical trials for use in preventing catheter-related infections. Cutanea Life Sciences holds the rights to develop omiganan as an acne treatment. Other clinical and pre-clinical drug candidates in the company's pipeline include potential treatments for Hepatitis B and C, blood infections, and neuro-degenerative diseases.

Pain Therapeutics, Inc. was founded in 1998 and is based in San Mateo, California. Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






